Grifols Sa (GRFS) Directors and Executive Officers

Officers & Directors

Grifols Sa currently has 3213 employees.

News about Grifols Sa Key Personnel

Yimmugo's $1 Billion Sales Projection in the US Fuels Grifols' Expansion, but Efforts Need to Boost ROI for Sustained Growth

Grifols, a leading global producer of plasma-derived medicines, has announced that its subsidiary, Biotest, anticipates generating approximately $1 billion in revenue from sales of its intravenous immunoglobulin (Ig) called Yimmugo over the next seven years in the United States. This positive forecast follows the recent approval by the Food and Drug Administration (FDA), allowing Yimmugo to be used in the treatment of primary immunodeficiencies (PID). However, despite this promising development, Grifols Sa s return on average invested assets (ROI) for the fourth quarter of 2023 was reported to be 0.94%, falling below its average ROI of 3.94%. This article will outline the facts and assess the impac...

Grifols Sets New Strategic Path with Sale of Equity Stake and Alliance with Haier Group

The agreement between Grifols and Haier Group signifies a significant development in the healthcare industry, with implications for both companies future growth and expansion. The deal has successfully obtained all necessary regulatory approvals and compliance confirmation from the Shenzhen Stock Exchange.
Grifols achieved a return on average invested assets (ROI) of 0.94% in its fourth quarter of 2023, a figure that falls below its average return on investment of 3.94%. This discrepancy in performance raises questions about the motivations behind the sale of the equity stake and the potential impact of the strategic alliance with Haier Group on Grifols overall profitability and growth trajectory....